Invitris, winner of last year's pre-seed competition m4 Award, convinced at the renowned business plan competition of Rice University and can now look forward to investment prizes totaling over 90,000 US dollars.
INVITRIS uses bacteriophages for the therapy of antibiotic-resistant infections and has developed a special technology with which it is possible for the first time to produce genetically optimized bacteriophages in vitro for the therapy of antibiotic-resistant infections. The spin-off from the Technical University of Munich already received funding from INCATE in March.
The Rice Business Plan Competition, hosted annually by the Rice Alliance for Technology and Entrepreneurship and Rice University's Jones Graduate School of Business, is the world’s largest and richest student start-up competition. This year’s edition saw 42 start-ups from 34 universities in four countries competing for more than USD 2 million in prizes.
They were selected from more than 400 applicants and competed in one of five categories: Energy, Clean Technology and Sustainability, Life Sciences and Health Solutions, Consumer Products and Services, Hardtech and Digital Enterprise.
The top prize was won by LIDROTEC, a startup from RWTH Aachen University that aims to increase production in the semiconductor industry.
About the m4 Award
With the m4 Award, initiated by BioM in 2011, the Free State of Bavaria promotes innovative products, technologies or services of young companies that decisively advance the further development of medicine of the future. The prize is awarded every two years. In the five rounds of competition so far, a total of 25 research projects have received awards. Nine spin-offs have been realized since then.